Who
Ali J. Satvat
Director
Company insider
Files Form 4 as: Director and 10% owner, BridgeBio Pharma; Director, Coherus Oncology; Director and 10% owner, Eidos Therapeutics.
In numbers
- Trades disclosed
- 57
- Buys
- 8
- Sells
- 0
- Bought
- $116.2M
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 6 Nov 2014
- Last trade
- 22 Jun 2026
- Last filed
- 24 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 22 Jun 2026filed 24 Jun 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Code A | —3,990 at $0.00 | filing |
| 22 Jun 2026filed 24 Jun 2026 | BBIO BridgeBio Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,277 at $0.00 | filing |
| 22 Jun 2026filed 24 Jun 2026 | BBIO BridgeBio Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,277 at $0.00 | filing |
| 22 Jun 2026filed 24 Jun 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Code A | —3,990 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | CHRS Coherus OncologyBiotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | CHRS Coherus OncologyBiotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 20 Jun 2025filed 24 Jun 2025 | BBIO BridgeBio Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,425 at $0.00 | filing |
| 20 Jun 2025filed 24 Jun 2025 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Code A | —6,589 at $0.00 | filing |
| 12 Jun 2025filed 13 Jun 2025 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —112,000 at $0.00 | filing |
| 30 Dec 2024filed 31 Dec 2024 | BBIO BridgeBio Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —79,702 at $0.00 | filing |
| 30 Dec 2024filed 31 Dec 2024 | BBIO BridgeBio Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —39,851 at $0.00 | filing |
| 30 Dec 2024filed 31 Dec 2024 | BBIO BridgeBio Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —39,851 at $0.00 | filing |
| 30 Dec 2024filed 31 Dec 2024 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Code M | $876K79,702 at $10.99 | filing |
| 30 Dec 2024filed 31 Dec 2024 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Code M | $665K39,851 at $16.68 | filing |
| 30 Dec 2024filed 31 Dec 2024 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Code M | $1.0M39,851 at $26.21 | filing |
| 21 Jun 2024filed 25 Jun 2024 | BBIO BridgeBio Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —26,014 at $0.00 | filing |
| 21 Jun 2023filed 23 Jun 2023 | BBIO BridgeBio Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —51,501 at $0.00 | filing |
| 22 Jun 2022filed 24 Jun 2022 | BBIO BridgeBio Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —104,921 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.